Enasidenib: A Targeted IDH2 Inhibitor for Acute Myeloid Leukemia

　　A Targeted Agent,Not Conventional Chemotherapy

　　Enasidenib is a targeted therapy—more precisely,an oral small-molecule inhibitor directed against the mutant IDH2 protein.Its therapeutic logic differs fundamentally from that of conventional chemotherapy:while chemotherapy acts mainly by killing rapidly dividing cells,enasidenib intervenes at a specific molecular abnormality within acute myeloid leukemia(AML)cells,placing it squarely in the category of precision targeted therapy.

　　Mechanism:From Metabolic Derangement to Differentiation

　　In some patients with AML,the IDH2 gene carries specific mutations that cause the aberrant IDH2 enzyme to produce excessive amounts of the oncometabolite 2-hydroxyglutarate(2-HG),which in turn disrupts normal cell differentiation.Enasidenib inhibits the activity of mutant IDH2,reducing the production of 2-HG and other abnormal metabolites,and promoting the maturation of abnormal myeloid cells toward more differentiated forms.On the basis of this mechanism,it is clearly classified as an IDH2 inhibitor.

　　Who Is Eligible:The Target Matters,Not the Label

　　Such precision also means the eligible population is clearly defined.In relapsed or refractory AML,the use of enasidenib requires confirmation of an IDH2 mutation.The decisive question,therefore,is not simply whether a patient"has leukemia,"but whether the corresponding molecular target is present.Genetic testing has become an essential prerequisite for selecting precision therapy,and treatment decisions should never rest on a disease label alone.

　　Safety:Targeted Does Not Mean Risk-Free

　　Enasidenib is a molecularly targeted agent rather than a conventional cytotoxic chemotherapy,and its use is guided by a clear molecular rationale.That said,targeted drugs are not without toxicity.Particular attention must be paid during treatment to characteristic risks such as differentiation syndrome,with monitoring and management carried out under specialist supervision.

　　In Brief

　　Enasidenib is a prototypical IDH2-targeted agent in the treatment of AML.Its principal advantage lies in addressing a defined molecular abnormality—provided the patient harbors the corresponding IDH2 mutation.For patients with AML,standardized genetic testing is the first step toward precision treatment.